Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | AKT1 | P31749 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CDC25A | P30304 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | PRKCG | P05129 | 2/20 | 0.43 |
| ▸ | PRKCB | P05771 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 2/20 | 0.43 |
| ▸ | PRKCH | P24723 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 2/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23016765 | 0.93 | LMNA (0.68) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL18970789 | 0.93 | LMNA (0.68) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL19089198 | 0.93 | LMNA (0.68) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL19089460 | 0.93 | LMNA (0.68) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL17832986 | 0.90 | LMNA (0.47) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL17817502 | 0.89 | CYP3A4 (0.57) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL17817225 | 0.88 | LMNA (0.46) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL17250758 | 0.87 | LMNA (0.44) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL27332023 | 0.86 | LMNA (0.41) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL17817230 | 0.85 | LMNA (0.58) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | LMNA 2135/4885AKT1 2455/4885ESR1 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.